---
title: "Weekly Recap | HENGRUI PHARMA +3.67%, consensus target above spot"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/304727940.md"
description: "Hengrui Pharma gained 3.67% this week to close at HK$52.20, while the Hang Seng Index rose 4.65%, meaning the stock underperformed the benchmark by about 0.98 percentage points. Trading across the four-session week was choppy: Monday (Nov 2) dipped to HK$49.80 before stabilising, Tuesday pushed higher to HK$51.65 on heavier volume, Wednesday touched the week’s high above HK$53.00, and Thursday faded back to HK$52.20. The weekly range was 7."
datetime: "2026-11-07T09:34:45.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/304727940.md)
  - [en](https://longbridge.com/en/news/304727940.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/304727940.md)
generator: "portal-rs"
---

# Weekly Recap | HENGRUI PHARMA +3.67%, consensus target above spot

## The Week

Hengrui Pharma (1276.HK) gained 3.67% this week to close at HK$52.20, while the Hang Seng Index rose 4.65%, meaning the stock underperformed the benchmark by about 0.98 percentage points. Trading across the four-session week was choppy: Monday (Nov 2) dipped to HK$49.80 before stabilising, Tuesday pushed higher to HK$51.65 on heavier volume, Wednesday touched the week’s high above HK$53.00, and Thursday faded back to HK$52.20. The weekly range was 7.25%, with average daily volume of about 3.975 million shares, below the 60-day median pace.

## Key Events

The most notable company development was FDA acceptance of the resubmitted biologics license application for camrelizumab, disclosed on Nov 4 and widely covered by news through the week. At the same time, the company reported cumulative A-share repurchases of 1.6362 million shares by end-October and cumulative cash dividends of roughly RMB 10.6 billion, underscoring its ongoing shareholder return efforts. On the business side, commentary around Q3 results continued to highlight rising contribution from new drugs and BD upfront payments as the company shifts toward an innovation-led model. Hengrui and Braveheart Bio also presented 52-week open-label extension data from a Phase 2 study in obstructive hypertrophic cardiomyopathy at the AHA Scientific Sessions, adding a pipeline update.

## Analyst Ratings

Coverage on Hengrui Pharma totals 11 institutions, with 8 buy and 3 overweight ratings, and no hold or under/sell views; the consensus rating is strong buy. The consensus target price is HK$77.81, implying about 49.07% upside from the current price. The target range runs from HK$55.26 to HK$121.37, showing a wide dispersion of views. Within the pharmaceutical sector, Hengrui ranks 6th among 29 covered names.

## The Week Ahead

The nearest macro data points after the latest session are Hong Kong’s unemployment rate on Tuesday, Nov 17 (prior 3.9%), and the Hong Kong CPI on Friday, Nov 20 (prior 1.9%). The next major company event is the FY2026 annual report, due after market close on Mar 25, 2027, with market estimates at EPS of 1.566 and revenue of about RMB 39.6 billion — still a longer-dated marker.

## In Short

Hengrui Pharma moved higher this week but lagged the broader market. FDA acceptance of the camrelizumab filing is the clearest company-level advance, with buybacks and dividends offering additional support. Broker ratings lean overwhelmingly positive, and the consensus target sits well above spot, though the wide target range reflects differing views on how quickly the innovation pipeline can deliver. Latest-day money flow shows a mixed picture across large and small orders, with no sustained direction yet. What matters next is how FDA review progress and shifts in FY2026 expectations are absorbed against current valuation.

*This article is generated by LongbridgeAI from market data, for information only and not investment advice.*

### Related Stocks

- [01276.HK](https://longbridge.com/en/quote/01276.HK.md)

## Related News & Research

- [Hengrui Announces Drug Inclusions in China’s 2026 NRDL](https://longbridge.com/en/news/305570916.md)
- [Hengrui Pharma reports 88.9% rise in 2026 third-quarter profit on licensing deals](https://longbridge.com/en/news/303205414.md)
- [The bank of Nvidia is getting more ‘disciplined,’ selective](https://longbridge.com/en/news/306148745.md)
- [PRESS DIGEST-New York Times business news - November 20](https://longbridge.com/en/news/306242079.md)
- [NetEase Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into NetEase (NTES)](https://longbridge.com/en/news/306200520.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**